文献速递神经肿瘤

在恶性胶质瘤成人患者中实施癌症管理与有意义生活(CALM):一项概念验证IIa期试验

Managing cancer and living meaningfully (CALM) in adults with malignant glioma: a proof-of-concept phase IIa trial.
PubMed 文献 · J Neurooncol · 2022-04-18

该概念验证IIa期试验纳入14例伴抑郁和/或死亡焦虑的胶质瘤成人患者(83%为胶质母细胞瘤,75%为女性,平均年龄56岁),评估CALM简短半结构化心理治疗的可行性、可接受性和初步效果。12例可评估,9例完成研究(保留率75%),3例因疾病进展退出;参与者报告高感知获益并全部推荐该方案,干预后死亡焦虑、广泛性焦虑和抑郁较基线下降,灵性增加,生活质量和癌症复发恐惧保持稳定。作者认为CALM在恶性胶质瘤成人中看似可行,结果支持在神经肿瘤学中进一步研究。

要点

  • CALM在恶性胶质瘤成人中看似可行,保留率为75%。
  • 干预后死亡焦虑、广泛性焦虑和抑郁较基线下降,灵性增加。
  • 生活质量和癌症复发恐惧在研究期间保持稳定。

核心结论

  • CALM在恶性胶质瘤成人中看似可行。
  • 入组率和保留率高,与晚期癌症患者心理治疗试验相当。
  • 参与者报告高感知获益以及死亡焦虑、广泛性焦虑和抑郁症状减轻。
  • 这些发现极其令人鼓舞,支持在神经肿瘤学中进一步研究CALM。

研究设计与样本

  • 概念验证IIa期试验,纳入14例伴抑郁和/或死亡焦虑症状的胶质瘤患者:83%为胶质母细胞瘤,75%为女性,平均年龄56岁(标准差15.1;范围27-81)。
  • 可行性基于既定指标评估;可接受性通过每次会谈后调查和干预后访谈测量。
  • 初步干预效果使用配对t检验探索,比较基线与干预后心理痛苦。
  • 14例入组患者中12例可评估,9例完成研究(保留率75%)。
  • 试验注册号NCT04646213,于2020年11月27日注册。

主要发现

  • 14例入组患者中12例可评估,9例完成研究(保留率75%)。
  • 3例患者因疾病大幅进展影响参与能力而退出。
  • 参与者报告高感知获益,且全部推荐该方案给他人。
  • 基线至干预后评估显示死亡焦虑、广泛性焦虑和抑郁减少,灵性增加。
  • 生活质量和癌症复发恐惧在整个研究期间保持稳定。

临床怎么用

  • 作者认为CALM在恶性胶质瘤成人中看似可行,并支持在神经肿瘤学中进一步研究CALM。

局限性

  • 3例患者因疾病大幅进展影响参与能力而退出。
  • 14例入组患者中仅12例可评估、9例完成研究(保留率75%)。
  • 作者结论称这些发现支持进一步研究CALM,原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Managing Cancer and Living Meaningfully (CALM) is an evidence-based, brief, semi-structured psychotherapy designed to help patients with advanced cancer cope with the practical and profound challenges of their illness. However, no study to date has investigated its feasibility, acceptability, and preliminary effectiveness in adults with malignant glioma, despite the well-documented incidence of psychological distress in this vulnerable and underserved population. METHODS: Fourteen patients with glioma and elevated symptoms of depression and/or death anxiety enrolled in the trial: 83% glioblastoma, 75% female, Mage = 56 years (SD = 15.1; range = 27-81). Feasibility was assessed based on established metrics. Acceptability was measured by post-session surveys and post-intervention interviews. Preliminary intervention effects were explored using paired t-tests, comparing psychological distress at baseline and post-intervention. RESULTS: Of the 14 enrolled patients, 12 were evaluable. Nine completed the study (75% retention rate). Three patients withdrew due to substantial disease progression which affected their ability to participate. Participants reported high perceived benefit, and all recommended the program to others. Baseline to post-intervention assessments indicated reductions in death anxiety, generalized anxiety, and depression, and increases in spirituality. Quality of life and fear of cancer recurrence remained stable throughout the study period. CONCLUSIONS: CALM appears feasible for use with adults with malignant glioma. Enrollment and retention rates were high and comparable to psychotherapy trials for patients with advanced cancer. High perceived benefit and reductions in symptoms of death anxiety, generalized anxiety, and depression were reported by participants. These findings are extremely encouraging and support further study of CALM in neuro-oncology. TRIAL REGISTRATION NUMBER: NCT04646213 registered on 11/27/2020.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Loughan AR, Willis KD, Braun SE, et al. Managing cancer and living meaningfully (CALM) in adults with malignant glioma: a proof-of-concept phase IIa trial. J Neurooncol. 2022. PMID: 35437687. doi:10.1007/s11060-022-03988-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。